Risk-prediction models specifically for hospitalized heart failure with preserved ejection fraction are lacking.
H
eart failure (HF) is a leading cause of hospital admissions and mortality among older adults in the United States. 1 Half of patients presenting with acute decompensated HF (ADHF) are estimated to have HF with preserved ejection fraction (HFpEF). 2, 3 Several risk-prediction models in HF exist, [4] [5] [6] [7] [8] some of which are derived from clinical trials and thus may be less applicable to the general HF population. Most are also restricted to patients with HF with reduced ejection fraction (HFrEF) and some are developed for ambulatory patients limiting the use for hospitalized patients. From the EFFECT (Enhanced Feedback for Effective Cardiac) study, risk scores were developed for 30-day and 1-year mortalities in ADHF regardless of ejection fraction (EF). 9 Although the EFFECT cohort consisted of both HFrEF and HFpEF, the scores have not been validated in a strict HFpEF population. Comprehensive risk-prediction models specifically developed for hospitalized patients with HFpEF are lacking.
No treatment has yet been convincingly shown to improve outcomes in HFpEF or in ADHF. A better insight into which factors relate to poor outcomes may help refine phenotypes for targeting with existing and potential novel treatment options. Moreover, early risk assessment at the time of hospital presentation may guide clinician, patient, and family decision making and identify patients in need of more intensive monitoring and therapy or palliative interventions.
Therefore, we used the Heart Failure Community Surveillance in the ARIC (Atherosclerosis Risk in Communities) Study to identify predictors of mortality and to create a risk-prediction model in patients with HFpEF hospitalized for ADHF.
METHODS

Study Population
Beginning in 2005, the Heart Failure Community Surveillance component of the ARIC study enumerates and validates HF hospitalizations from 21 hospitals from 4 United States communities (Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; and Washington County, MD). Methods of event ascertainment and classification have been described previously. 10 A stratified random sample of eligible hospitalizations for HF is selected based on a HF-related International Classification of Disease, Ninth Revision, Clinical Modification codes in any position (Appendix Table I in the Data Supplement), age ≥55 years at the time of hospital discharge, and home address within the ARIC communities. The sampling fractions vary by International Classification of Disease, Ninth Revision, Clinical Modification discharge codes (428 and non-428), ARIC field center, sex, and race (by race in Forsyth County and Jackson only) to achieve similar standard errors for HF event rates across these strata. Medical records are abstracted by trained medical personnel. Abstracted hospitalizations are classified by physician review or computer algorithm as definite or possible ADHF, chronic stable HF, and HF unlikely or unclassifiable. ADHF is classified if there is evidence of worsening HF symptoms requiring augmentation of therapy while chronic stable HF is selected if there is evidence of HF without change in symptoms.
We excluded hospitalizations with EF <50%, EF ≥50% with prior EF <50%, and EF missing. We further excluded hospitalizations of ADHF developed during hospitalization (rather than at time of admission), with unknown status at followup, and race other than black or white. Hospitalizations from 2005 to 2011 were used as a derivation sample and from 2012 to 2013 as a validation sample (flow chart; Figure 1 ). EF was based on inpatient diagnostic tests or, when absent, preadmission imaging studies (within 2 years before hospitalization). Direct linkage of individual patients to hospitalizations was not possible, thus the study is based on hospitalizations and not unique patients.
Statistical Methods
Baseline characteristics were compared between patients alive versus dead at 28-day and 1-year post-admission using t test and Pearson χ 2 statistic with Rao-Scott correction for survey data. 11 Data were reported as mean±standard error for continuous variables and percentages for categorical variables. Because of skewed distribution, brain natriuretic peptide (BNP) and NT-proBNP (N-terminal pro-B-type natriuretic peptide) were log transformed for modeling, and geometric means are shown for descriptive purposes.
WHAT IS NEW?
• Our study provides further evidence that patients hospitalized with new onset or worsening symptoms of heart failure with preserved ejection fraction (HFpEF) face a high risk of death with about one third of the patients being dead within a year.
• Several risk scores in heart failure exist, but comprehensive risk-prediction models specifically developed for patients with HFpEF are lacking.
• We created a risk-prediction model for patients with HFpEF hospitalized for acute decompensated heart failure.
WHAT ARE THE CLINICAL IMPLICATIONS?
• A better insight into which factors relate to poor outcomes may help refine phenotypes for targeting with existing and potential novel treatment options. Hence, a potential use of a risk-prediction model in this population may be in future trial design of HFpEF and acute decompensated heart failure.
• Despite the lack of evidence-based treatment in HFpEF, risk-prediction models may be useful in daily practice, guiding clinical decision making about early patient triage, in-hospital monitoring, and treatment, as well as early follow-up after discharge.
• Estimates of mortality may provide patients and family realistic expectations about prognosis.
The index date was date of hospital admission. Outcomes were all-cause mortality within 28 days and within 1 year from index date. We used variables from the previously developed EFFECT score that were available in our data set and created a modified EFFECT score using the scoring system from the EFFECT risk-prediction model (Appendix Table II in the Data Supplement). 9 The variables in the modified EFFECT score included age, systolic blood pressure, blood urea nitrogen sodium, cerebrovascular disease (defined as stroke/transitory ischemic attack in ARIC), chronic obstructive pulmonary disease (COPD), and hemoglobin. Variables from the EFFECT score not available in our data set were respiratory rate, dementia, hepatic cirrhosis, and cancer. To improve model performance in HFpEF, we selected 27 clinically relevant baseline variables as potential predictors that could be added to the modified EFFECT score. The modified EFFECT score variable and the other candidate variables were used in a stepwise forward logistic regression with a P value of 0.2 as criteria for entering the model. Then the variables were eliminated in a stepwise fashion until discrimination was impacted (defined as a drop in area under the curve [AUC] by >0.015 from the full model). For variables with >5% missing, we performed simple imputation using the sample mean for missing values.
Continuous variables were fitted as continuous in the initial models unless there was clear evidence of nonlinearity. The appropriateness of the linearity assumption was tested using spline analysis with the best fitting number of knots (3) (4) (5) . Body mass index (BMI) showed a nonlinear pattern and was categorized in 4 categories according to prior literature (underweight BMI <18.5, normal BMI 18.5-24.9, overweight BMI 25.0-29.9, obese BMI ≥30 kg/m 2 ). When included in the modified EFFECT score, sodium and hemoglobin were categorized as in the original EFFECT score (sodium < or ≥ 136 mEq/L and hemoglobin < or ≥ 10.0 g/dL, respectively).
Because some hospitals use BNP and others NT-ProBNP, these variables were combined, first assessing a log transformation and standardization and then combining the variables into one. NT-ProBNP was log transformed for 2 age categories (≤75 and >75 years). The assessed odds ratios for BNP and NT-proBNP are per increase of 1 standard deviation of the log-transformed values. For hospitalizations with both BNP and NT-ProBNP (n=4), BNP was used in the analysis. In ARIC, hypoxia is defined as oxygen saturation <90% or the term hypoxia stated in the medical record. Anemia is defined as previous hemoglobin levels of <12.0 g/dL for women and 13.0 g/dL for men or history of anemia stated in the record. For blood pressure and heart rate, the first documented levels in the record at the day of admission are recorded.
The reduced logistic regression models for 28-day and 1-year mortalities were used to create risk scores for predicting short-and intermediate-term mortality after admission. We converted the coefficients in the models into integer points in a risk score. Each integer is a rounding of the coefficient in the logistic regression models making the log odds ratio 0.1 equivalent to 1 point. For the risk scores, continuous variables were grouped into convenient intervals.
The risk score is directly related to the mortality at 28 days and 1 year in the 2 models, respectively. Zero points represent the lowest risk and the score increases by an integer amount for each risk factor level above the lowest risk.
Discrimination of the risk scores was assessed by calculating AUC values and calibration by plotting predicted versus observed mortality by deciles of predicted probability and by the Hosmer-Lemeshow statistic. Temporal validation of the developed risk scores and the modified EFFECT score alone and was performed by assessing discrimination and calibration in the latest additions to the data set (year 2012-2013). Because of a relatively small sample size, the calibration plots and Hosmer-Lemeshow statistic are performing using quintiles in the validation sample.
All statistical analyses accounted for the stratified sampling design and weighted the observations by the inverse of the sampling fractions. Analyses were performed using Stata version 14.1 (Stata Corp., College Station, TX). Institutional review board approvals were obtained by each participating ARIC Study field center (the Universities of Mississippi and Minnesota, Wake Forest University, and Johns Hopkins University) and the coordinating center (University of North Carolina). The research was conducted in accordance with the principles described in the Declaration of Helsinki.
RESULTS
Baseline Characteristics and Mortality
From 2005 to 2013, there were 20 911 eligible hospitalizations sampled in ARIC which represented a larger population of 87 342 hospitalizations. Of these, 8145 sampled hospitalizations were defined as probable or definite ADHF. After additional exclusions as above, a study sample of 2673 HFpEF hospitalizations representing a weighted sample of 12 612 remained (flow chart; Figure 1 ). EF was based on inpatient diagnostic tests in 80% of the hospitalizations, and in the remaining 20%, EF was based on preadmission evaluation performed no longer than 2 years before the The Table depicts baseline characteristics for the derivation sample by 28-day and 1-year mortalities. Mean age was 77 years, 65% were women, and 74% were white. Sixty-five percent had a prior diagnosis of HF and 29% had a prior hospitalization for HF. BMI was missing in 16% of the hospitalizations, and the combined variable of BNP and NT-proBNP was missing in 12%. Simple imputation was performed on these variables; all other variables had <5% missing, and complete case analysis was performed.
Mortality in the derivation sample was 11% at 28 days and 34% at 1 year. In-hospital mortality was 6%. Those who died were older and more likely to be white. They were also more likely to be underweight and have a history of atrial fibrillation/flutter, anemia, pulmonary hypertension, and valvular heart disease and higher natriuretic peptide levels. Excluding in-hospital deaths, 28-day and 1-year mortalities were 6% and 30%, respectively. Baseline characteristics for the validation sample is depicted in Appendix Table III 
Predictors of Mortality
After imputation, <7% of the observations had any of the remaining variables missing, and the stepwise logistic regression models were based on a total of 1720 nonweighted (ie, representing 7957 weighted) observations. After the stepwise regression, 4 and 8 variables were removed to result in the final models for 28-day and 1-year mortalities, respectively. The modified EFFECT score as a composite variable was the most powerful predictor of both 28-day and 1-year mortalities ( Figure 2 ).
Higher heart rate, underweight (defined as BMI <18.5), and higher natriuretic peptide levels were predictors in both models whereas white race was identified as a predictor in the 28-day mortality model, and history of atrial fibrillation/flutter was identified predictors in the 1-year mortality model.
Discrimination of the models measured as AUC values was 0.76 for 28-day mortality and 0.72 for 1-year mortality. To maintain appropriate discrimination of the models, 2 predictors with P<0.10 were kept in the model for 28-day mortality (natriuretic peptides, P=0.076 and heart rate, P=0.095). All other predictors had P<0.05.
Risk Score
From the identified predictors, separate risk scores for 28-day and 1-year mortalities were created. The probability of dying within 28 days and 1 year was estimated by summing the points assigned for each value of the predictors. A web-based calculator is available at http:// www2.cscc.unc.edu/aric/Calculator/HFpEF-Risk.html providing a simple tool for prediction of mortality at 28 days and 1 year (the scoring system is shown in Appendix Table IV in 
Overall, the mean observed 28-day and 1-year mortalities in the derivation sample was 11% and 34%, respectively, and the corresponding mean predicted numbers using the risk score were 10% and 33%. Discrimination of the risk scores was good (AUC 0.76 and 0.72 for 28-day and 1-year mortalities, respectively). Calibration was also acceptable as shown with Hosmer-Lemeshow statistics (risk score P value 0.48 and 0.33 for 28-day and 1-year mortalities) and the plots of predicted versus observed mortality by deciles of predicted mortality (Figure 4) . The observed mortality increased by >30-fold across deciles of risk score.
Validation of the Risk Score
Mortality in the validation sample was 8% at 28 days and 31% at 1 year, the corresponding mean predicted numbers using the risk score were 7% and 29%. Distribution of the risk scores in the validation sample and the association with predicted mortality are shown in Figure 5 . Risk score discrimination in the validation sample was only slightly weaker than in the derivation sample (AUC 0.73 and 0.71 for 28-day and 1-year mortalities, respectively). Calibration was acceptable as shown with Hosmer-Lemeshow statistics (risk score P value 0.51 and 0.29 for 28-day and 1-year mortalities) and the plots of predicted versus observed mortality in Figure 6 .
Discrimination of the modified EFFECT score alone in the validation sample was weaker than our developed models (AUC 0.70 and 0.68 for 28-day and 1-year mortalities, respectively). Calibration of the modified EFFECT score alone was acceptable (Hosmer-Lemeshow P value 0.70 and 0.99 for 28-day and 1-year mortalities, respectively)
DISCUSSION
In this large generalizable community sample of patients ≥55 years of age hospitalized with ADHF and preserved EF from the Heart Failure Community Surveillance in the ARIC Study, mortality was 11% at 28 days and 34% at 1 year. Simple clinical variables at hospital admission were shown to be strongly associated with increased mortality. We generated risk scores that provide a simple and clinically useful tool to evaluate 28-day and 1-year risk of death at the time of hospital presentation for HFpEF patients with ADHF. The high mortality for patients hospitalized with ADHF and preserved EF of 6%, 11%, and 34% in-hospital, 28 day, and 1 year, respectively, are consistent with data from the Olmsted county on hospitalized patients with HFpEF and the EFFECT study from Ontario, Canada, on ADHF, including both patients with HFpEF and HFrEF. 2, 9 Studies with both ambulatory and hospitalized patients like the MAGGIC (Meta-analysis Global Group in Chronic Heart Failure) and the Swedish Heart Failure Registry report lower mortality in HFpEF. 12, 13 The much lower mortality rates in HFpEF trials, such as CHARM-Preserved 14 (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity-Preserved) and I-PRESERVE (Irbesartan in Heart Failure With Preserved EF), 15 are likely explained by a different patient selection including younger populations, lower comorbidity-burden, and clinically stable patients. The Heart Failure Community Surveillance in ARIC distinctly differentiates between ADHF and chronic stable HF which most likely contributes to a higher specificity in identifying true ADHF hospitalizations than other classification criteria (Framingham) or simply International Classification of Disease codes. The ARIC classification of ADHF requires clear evidence of HF with active decompensation. Furthermore, 28-day and 1-year mortalities are from admission date, and in-hospital deaths are included in these numbers. Exclusion of in-hospital deaths (n=100 nonweighted hospitalizations) gave slightly lower mortality rates at 28 days and 1 year.
Because the EFFECT score has been shown to be a good risk prediction tool in ADHF including the whole EF spectrum, we used the available variables from the EFFECT score as a basis for developing our new HFpEF risk score. Indeed, the composite modified EFFECT score variable, including age, systolic blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, and COPD, was a powerful predictor of mortality also in HFpEF. By adding covariates to this composite variable, we could improve model performance compared with the modified EFFECT Values represent mean±SE or % unless stated. The numbers and percentages listed are weighted to account for sampling fractions (total 8578 weighted and 1852 nonweighted sampled events). ACEi indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARIC, atherosclerosis in the community; BMI, body mass index; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; JVD, jugular venous distension; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PND, paroxysmal nocturnal dyspnea; RAS, renin-angiotensin system; and TIA, transitory ischemic attack.
*Variables used as potential covariates for the models. †Worst value refers to the highest value with the exception of hemoglobin and sodium, where it refers to the lowest value. ‡Geometric means. score alone. The potential additional covariates included in our analyses were chosen based on prior knowledge and clinical relevance, and specifically, because of availability in the initial hours of hospitalization for early risk prediction, prioritization, and triage. Because EF has been shown to be less prognostic when higher than 40% to 45% 12,16 and our inclusion criterion was EF ≥50%, EF was not included in the list of potential covariates.
Despite their dominant role in diagnosis and as treatment targets in ADHF, HF signs and symptoms have not frequently been evaluated as covariates for risk prediction in other studies. In ADHERE (The Acute Decompensated Heart Failure National Registry), dyspnea at rest was evaluated as a potential risk predictor, whereas Get with the Guidelines and OPTIMIZE-HF (The Organized Program to Initiate Life-Saving Treatment in Hospitalized Patients With Heart Failure) did not evaluate any signs or symptoms as potential predictors of mortality. We included shortness of breath, edema, and hypoxia at admission and found hypoxia to be an important and to our knowledge novel predictor of both 28-day and 1-year mortalities.
Poor and worsening renal function, higher heart rate, and lower hemoglobin, BMI, and systolic blood pressure have all previously been shown to be strong predictors of mortality in HF. 9, [17] [18] [19] [20] [21] White race was a predictor of increased 28-day mortality, consistent with the findings from the risk-prediction models from Get with the Guidelines and OPTIMIZE-HF. 17, 19 Comorbidities frequently associated with mortality in chronic HF, such as diabetes mellitus and COPD, were not confirmed to be significant predictors. These comorbidities may be relatively less important in an acute setting, where hemodynamic, metabolic, and cardiorenal parameters are more reflective of the severity and progression of the HF syndrome and poor shortand intermediate-term outcomes. However, COPD was a significant predictor in the EFFECT score and thus included in our model as part of the modified EFFECT score. Interestingly, the most powerful predictors in our model represent different organ systems and aspects of the proposed pathophysiology of HFpEF. Risk scores in HF are useful beyond improved discrimination and calibration of risk. They simplify and standardize the risk assessment in an otherwise heterogeneous and complex group of patients and encourage more rigorous and quantitative clinical assessment. 22 Most risk scores have been geared toward chronic HF and HFrEF for distinct purposes, such as transplantation selection. 4, 23 In contrast, our risk score was developed for a strict HFpEF population where to date no convincing evidence-based treatment exists. The potential use is, therefore, in ADHF trial design (where HFpEF and HFrEF are often both included). Furthermore, HFpEF is a growing public health concern affecting elderly and comorbid patients 24 where patient triage, decisions about inpatient and postdischarge healthcare resource use, and patient and family preferences and decision making are all informed by pragmatic and simple yet comprehensive tools for 28-day and 1-year prognostications.
Our findings must be considered in the context of some limitations. First, because of limitations of the data set, we were not able to link individual patients to hospitalizations. Thus, the study is based on hospitalizations and not unique patients. With a mean sampling fraction of 0.213 and a prior HF hospitalization in ≈30%, ≈6% of the events could possibly be rehospitalizations from patients already existing in the data set. Because rehospitalized patients are known to have worse outcomes, our mortality rates may be slightly overestimated. Second, biochemical variables in ARIC are recorded as worst and last during hospitalization. We have used worst in the prediction models assuming that these variables are from admission/early part of hospitalization. We consider this an acceptable assumption considering that these patients have an acute condition at admission. Because of the complexity of our data and the variable selection process used, we chose to perform simple imputation of missing values using the sample mean for BMI and natriuretic peptides despite the fact that single imputation is generally considered inferior to multiple imputation. This may have resulted in biased estimates of the 2 parameters and their variances. The developed risk scores were validated using hospitalized acute HFpEF in the last 2 years of this study period, year 2012 through 2013, comprising 821 events including 64 deaths at 28 days and 252 at 1 year. This is a small validation sample with few outcome events but sufficient to validate the risk scores with good discrimination and calibration. An important next step is to validate the risk score in a different cohort.
Because not all variables from the EFFECT model were available in our data, we could not validate the complete EFFECT score and we can only compare our risk scores with the modified EFFECT score.
Among the strengths of our report is the use of a large biracial community sample from >20 hospitals in 4 diverse United States Communities, leading to generalizable and externally valid findings. Record abstraction is rigorously standardized with HF hospitalizations systematically classified and adjudicated by a panel of physician reviewers, lending reliability and internal validity to the findings.
In conclusion, this study provides further evidence that patients hospitalized with new onset or worsening symptoms of HFpEF face a high risk of death. The modified version of the EFFECT score, including age, systolic blood pressure, blood urea nitrogen, sodium, cerebrovascular disease, COPD, and hemoglobin, was a powerful predictor of mortality. The novel risk scores provide estimates of mortality that can guide clinician decision making on in-hospital monitoring and treatment, as well as early follow-up after discharge.
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